anastrozole has been researched along with Cardiovascular Diseases in 9 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anastrozole is an oral aromatase inhibitor that normalizes serum testosterone levels and decreases oestradiol levels modestly in elderly men with mild hypogonadism." | 5.11 | Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. ( Dougherty, RH; Hayden, D; Leder, BZ; Rohrer, JL; Rubin, SD, 2005) |
| "The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women." | 4.84 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. ( Fabian, CJ, 2007) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "MA." | 2.82 | Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. ( Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, JA | 1 |
| Shepherd, LE | 1 |
| Ingle, JN | 1 |
| Muss, HB | 1 |
| Pritchard, KI | 1 |
| Gelmon, KA | 1 |
| Whelan, TJ | 1 |
| Elliott, C | 1 |
| Goss, PE | 1 |
| Dougherty, RH | 1 |
| Rohrer, JL | 1 |
| Hayden, D | 1 |
| Rubin, SD | 1 |
| Leder, BZ | 1 |
| Esteva, FJ | 1 |
| Hortobagyi, GN | 1 |
| Bunck, MC | 1 |
| Toorians, AW | 1 |
| Lips, P | 1 |
| Gooren, LJ | 1 |
| Lewis, S | 1 |
| Fabian, CJ | 1 |
| Perez, EA | 1 |
| Wengström, Y | 1 |
| Coates, A | 1 |
| Mouridsen, H | 1 |
| Thürlimann, B | 1 |
5 reviews available for anastrozole and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
3 trials available for anastrozole and Cardiovascular Diseases
| Article | Year |
|---|---|
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardio | 2016 |
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Topics: Aged; Analysis of Variance; Anastrozole; Aromatase Inhibitors; Biomarkers; C-Reactive Protein; Cardi | 2005 |
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
Topics: Anastrozole; Androgens; Aromatase Inhibitors; Bone and Bones; C-Reactive Protein; Cardiovascular Dis | 2006 |
1 other study available for anastrozole and Cardiovascular Diseases
| Article | Year |
|---|---|
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2008 |